Biopharma Industry Stakeholders Advance Labcorp’s Global Trial Connect Platform in Addressing Key Clinical Trial Delivery Challenges

BURLINGTON, N.C. (February 12, 2025) – Labcorp, a global leader of innovative and comprehensive laboratory services, has expanded engagement efforts with key stakeholders across the clinical trials ecosystem that are helping to advance its Global Trial Connect portfolio to deliver solutions addressing key clinical trial delivery challenges.

"Today’s clinical trials are increasingly complex and face mounting pressure to deliver results faster—all while maintaining high standards of quality," said Mark Slette, Head of Global Operations and Strategic Transformation, Central Laboratory Services, and lead for the Labcorp Global Trial Connect solution. "That’s why we’re working closely with biopharma sponsors, investigator sites and ecosystem partners to directly address critical areas that open up efficiency and patient options within clinical trials.”

Engaging with Biopharma Sponsors to Enhance Trial Efficiency
Labcorp actively collaborates with sponsors to gather insights and deliver operational, technology and data enhancements that address lengthy timelines, delays in study start-up and high costs related to kit wastage. 

• Customer Advisory Boards: Labcorp hosts regular advisory board meetings with leading biopharma sponsors to identify key pain points and evaluate new platform features intended to address them.
• Proof of Concept Testing: Sponsors preview new Global Trial Connect features and provide direct feedback, helping to implement solutions that are impactful and aligned with their needs.

“Our Customer Advisory Board, made up of key experts from leading global biopharma companies, has been instrumental in driving a deeper understanding of pain points as well as given us early feedback on service and solution concepts in development to ensure that we’re fully addressing our customers’ needs while keeping the user experience in mind,” said Robin Carson, Senior Vice President of Global Client Delivery and Strategic Partnerships, Central Laboratory Services, at Labcorp.

Focusing on Site Needs to Optimize Day-to-Day Operations
Labcorp engages investigator sites to understand their unique challenges and optimize their workflows to enable more time for patients. The company gathers site feedback through a combination of detailed surveys and in-person visits. 

• Product Surveys: Labcorp regularly surveys sites to assess usability and identify feature needs with existing and future applications.
• Site Listening Tour: In 2024, Labcorp’s user experience, product and development teams conducted site visits across the U.S. to observe workflows and speak with site personnel. These visits are expanding to Europe and Asia in 2025.

Daniel Marangoni, Ph.D., Head of Oncology Site Operations at Circuit Clinical, praised how Labcorp is investing in better understanding the site experience. Marangoni shared "We recently hosted Labcorp and walked them through our day-to-day workflows. We appreciate that they took the time to really understand what we do and look forward to seeing how their new tools can give us more time to do the work that we love with our patients."  

Holistic Solutions through Strategic Industry Relationships
Labcorp leverages strategic relationships with key industry stakeholders such as Hawthorne Health, Circuit Clinical and Acclinate alongside its decentralized trial offerings to improve patient access, diversity and retention.

“We believe collaboration is key to solving key challenges around clinical trial optimization. By working with stakeholders across the trial lifecycle—from biopharma sponsors to sites to patients—we’re providing meaningful answers to shared pain points in a holistic way,” added Slette.

Looking Ahead to 2025: Continued Innovation 
Labcorp remains committed to advancing its Global Trial Connect portfolio, with new enhancements planned for 2025 focused on continued optimization of site workflows, driving cost savings and improving sustainability with supply management advances and greater access to insights that accelerate study timelines.

For more information about Global Trial Connect, visit https://www.labcorp.com/biopharma/central-labs/global-trial-connect.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to the anticipated benefits of, and future updates to, the company’s Global Trial Connect platform.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward- looking statements.

The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K, and subsequent Forms 10-Q, under the heading “MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS”.

About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com.